Bone Biologics Corp
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
BBLG$0.34+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations
| Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | |
|---|---|---|---|---|
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |
| Revenues · $ · - · $ · - · $ · - · $ · - | ||||
| Operating expenses | ||||
| Research and development | 350,442 | 2,295,251 | 596,067 | 4,885,896 |
| General and administrative | 459,223 | 744,617 | 1,117,135 | 1,301,509 |
| Total operating expenses | 809,665 | 3,039,868 | 1,713,202 | 6,187,405 |
| Loss from operations | (809,665) | (3,039,868) | (1,713,202) | (6,187,405) |
| Other expenses | ||||
| Change in fair value of warrant liability | 10,785 | 1,270,202 | 48,096 | 707,284 |
| Interest income | 15,147 | 428 | 15,403 | 984 |
| Total other income (expenses) | 25,932 | 1,270,630 | 63,499 | 708,268 |
| Net Loss | $(783,733) | $(1,769,238) | $(1,649,703) | $(5,479,137) |
| Weighted average shares outstanding – basic and diluted | 1,168,423 | 339,308 | 915,931 | 295,031 |
| Loss per share – basic and diluted | $(0.67) | $(5.21) | $(1.80) | $(18.57) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.